Skip to content
VectorGene
ar
المحتوى السريري والتقني متاح باللغة الإنجليزية.

Technology transfer platform

CAR-T Manufacturing

End-to-end support for hospitals and biotechnology organisations to establish CAR-T manufacturing and clinical treatment capability, from GMP facility planning to first clinical use.

Discuss local capability

Typical timeline
12–24 months

Researcher measuring a cell culture volume. Illustrative stock photograph.

Capabilities to transfer

Workflows, expertise and systems designed around your local institution.

GMP facility planning
Cleanroom layout, classification and equipment specification.
CAR-T workflow transfer
Multi-target platforms: CD19, CD20, CD22, BCMA, CD7, GPRC5D, BAFF-R.
SOP & batch records
Full documentation set with local adaptation.
QC & release testing
Specification setting and release criteria.
Vector / plasmid strategy
Supply, qualification and contingency planning.
Staff training
Laboratory, clinical, regulatory and quality personnel.
Clinical protocol support
Trial design and ethics submission preparation.
CRS / ICANS management
Clinical governance and adverse event frameworks.

What does your institution need first?

Begin with your existing infrastructure, clinical governance and local regulatory pathway. Feasibility establishes the programme requirements.

Discussion preparation

Your institutional baseline

0/4

Use these prerequisites to prepare a discussion. This checklist is not a clinical assessment or a determination of regulatory readiness.

0 of 4discussion prerequisites identified.

Partner-reported portfolio

CAR-T target explorer

Seven single-antigen and four dual-antigen constructs. Explore the portfolio as a starting point for technical discussion.

Single-antigen constructs

Dual-antigen constructs

Partner-reported construct portfolio. Target selection does not establish clinical suitability, regulatory approval or efficacy. Availability and local requirements are assessed during feasibility.

Partner-reported · generalised proposal

Typical engagement

Indicative engagement only. The actual programme depends on feasibility, local infrastructure and the host country regulatory framework.

Knowledge transfer

2–3 technical personnel deployed on-site · hands-on training for 8–10 local staff · ongoing remote and in-person support · structured knowledge-transfer programme.

Facility

~1,000+ m² GMP laboratory (Grade B/A), emergency power, CO₂ incubators & bioreactors, biosafety cabinets, automated transfection, ultracentrifuges & purification, flow cytometry, PCR & QC.

Clinical

a transplant ward or laminar-flow ward led by the local clinical team under specialist guidance; pre-clinical studies (including animal studies) per local policy; approvals coordinated with local regulators.

Manufacturing and care need a shared operating plan.

A local CAR-T programme connects collection, manufacture, quality review and clinical delivery. Feasibility should follow the full institutional pathway, including the interfaces between teams. The equipment specification alone cannot describe every responsibility or establish that a programme is ready to proceed.

One pathway. Shared responsibilities.

  1. Collection
  2. Manufacture
  3. Quality review
  4. Clinical delivery

Questions for the programme brief

Which product and intended use?

Establish the proposed cell source, construct, indication, development stage and access rights before defining the transfer scope.

How are handovers controlled?

Review collection, identity records, manufacturing scheduling, release responsibilities and arrangements when a batch cannot proceed.

Who leads continuing oversight?

Name manufacturing, quality and clinical owners, including the team responsible for safety reporting and follow-up planning.

What to prepare for review
  • Product and clinical-pathway brief
  • Facility and workforce baseline
  • Proposed quality, release and follow-up responsibilities

FDA’s CAR-T development guidance covers manufacturing controls, nonclinical development, clinical study design and analytical comparability. It distinguishes product-specific considerations for autologous and allogeneic approaches.

FDA: Considerations for the Development of CAR T Cell Products

External references explain the wider context. They do not verify or endorse the supplied VectorGene or partner offering.

Working environments

A working cell-manufacturing environment.

Illustrative stock photography provides context for the people, processes and working environments behind this capability.

Plan the working environment.

Explore three cutaway laboratory rooms with workbenches and air-handling panels. This is an illustrative object, not a facility specification.

Scope
Establish the proposed cell source, construct, indication, development stage and access rights before defining the transfer scope.
Handover
Review collection, identity records, manufacturing scheduling, release responsibilities and arrangements when a batch cannot proceed.
Oversight
Name manufacturing, quality and clinical owners, including the team responsible for safety reporting and follow-up planning.
All three review topics are shown.
Scientist removing growth medium from a multiwell plate. Illustrative stock photograph.
Scientist removing growth medium from a multiwell plate
Technician inspecting an environmental monitoring plate. Illustrative stock photograph.
Technician inspecting an environmental monitoring plate
Laboratory technicians reviewing a software platform. Illustrative stock photograph.
Laboratory technicians reviewing a software platform
Cleanroom floor cleaning in protective clothing. Illustrative stock photograph.
Cleanroom floor cleaning in protective clothing

Start a conversation

Discuss CAR-T Manufacturing

Prepare a partnership enquiry with this platform selected. Local approval and regulatory dossier ownership remain with the local institution.
Partner with us